COVITREM-1 - Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19

Head :GIBOT Sébastien

Last update : 05/06/2021 | Version : 1 | ID : 73586

General

Identification

Detailed name	Prognostic value of measuring the activation pathway for Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) in patients hospitalised due to COVID-19
Sign or acronym	COVITREM-1
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	NCT04544891

General Aspects

Medical area	Anesthesiology ? Intensive care Infectious diseases
Study in connection with Covid-19	Yes
Pathology (details)	patients hospitalised due to Covid-19
Keywords	biomarker, COVID-19

Scientific investigator(s) (Contact)

Name of the director	GIBOT
Surname	Sébastien
Email	s.gibot@chru-nancy.fr
Organization	Nancy Regional University Hospital

Collaborations

Participation in projects, networks and consortia	Yes

Funding	
Funding status	Public
Details	BPI France
Governance of the database	
Sponsor(s) or organisation(s) responsible	Nancy Regional University Hospital
Organisation status	Public
Presence of scientific or steering committees	Yes
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	Evaluate the prognostic value of initial TREM-1 activation (first measurement collected) on clinical deterioration in patients hospitalised due to COVID-19 in medical, emergency and intensive care departments
Inclusion criteria	Patients aged over 18 years Hospitalised for less than 3 days for any reason whatsoever, but screened for Covid-19. SARS-CoV-2 infection should be "probable" or "confirmed" according to the definition published on 3 April by Santé Publique France (French Public Health Agency): laboratory confirmation (by positive RT-PCR further to nasopharyngeal sample or any other

	sample and/or positive serology indicating infection) or by a composite endpoint combining characteristic pulmonary impairment upon imaging and clinical/laboratory effects suggesting viral infection (including: fever, cough, chest pain, and biological inflammatory syndrome, lymphopenia, elevated liver enzymes). Registered with a social security scheme or a beneficiary of such a scheme The patient or their representative will have received information on the study and signed the emergency informed consent/inclusion form in compliance with Article L.1122-1-3 of the French Public Health Code (CSP)
Population type	
Age	Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	J96 - Respiratory failure, not elsewhere classified
Gender	Male Woman
Geography area	National
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1009
Data	
Database activity	Current data collection
Type of data collected	Clinical data

	Biological data
Clinical data (detail)	Direct physical measures
Presence of a biobank	Yes
Contents of biobank	Serum Plasma DNAc/RNAm
Health parameters studied	Health event/morbidity Health event/mortality
Procedures	
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the participant (mail, e-mail, telephone etc.)
Links to administrative sources	No
Promotion and access	
Promotion	
Access	